The standard care of cancer therapy is highly dependent on the cancer type, stage and patients themselves. Consequently, for most cancers there is only marginal improvements in patient survival rates. Undetected/unremoved cancer during surgery and resistance to treatments such as chemo and radiation therapy, are major causes for a poor prognosis. To tackle these issues, research in my lab focuses on i) development of small molecule fluorescent chemosensors as diagnostic tools that can be used to predict anticancer drug resistance for personalized medicine, and ii) development of cancer selective probes for photodynamic therapy that will enable simultaneous real-time fluorescence imaging and destruction of cancerous tissue with high selectivity over healthy tissue. In this presentation, I will discuss progress in developing small molecule activatable probes that exploit overexpressed levels of enzymes found in a variety of cancers for applications in cancer biology.<br/>

Light-activatable probes for cancer biology

2019 Spring National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.